Full Text:   <1819>

CLC number: R734.2

On-line Access: 2013-03-06

Received: 2012-03-29

Revision Accepted: 2012-07-29

Crosschecked: 2013-02-28

Cited: 16

Clicked: 3353

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2013 Vol.14 No.3 P.207-215

10.1631/jzus.B1200101


Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population


Author(s):  Wei Hong, Kai Wang, Yi-ping Zhang, Jun-yan Kou, Dan Hong, Dan Su, Wei-min Mao, Xin-min Yu, Fa-jun Xie, Xiao-jian Wang

Affiliation(s):  Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China; more

Corresponding email(s):   zhangyp126@hotmail.com

Key Words:  Non-small cell lung cancer, Single nucleotide polymorphism, Methylenetetrahydrofolate reductase, Gemcitabine, Excision repair cross-complementation group 1


Wei Hong, Kai Wang, Yi-ping Zhang, Jun-yan Kou, Dan Hong, Dan Su, Wei-min Mao, Xin-min Yu, Fa-jun Xie, Xiao-jian Wang. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population[J]. Journal of Zhejiang University Science B, 2013, 14(3): 207-215.

@article{title="Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population",
author="Wei Hong, Kai Wang, Yi-ping Zhang, Jun-yan Kou, Dan Hong, Dan Su, Wei-min Mao, Xin-min Yu, Fa-jun Xie, Xiao-jian Wang",
journal="Journal of Zhejiang University Science B",
volume="14",
number="3",
pages="207-215",
year="2013",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1200101"
}

%0 Journal Article
%T Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population
%A Wei Hong
%A Kai Wang
%A Yi-ping Zhang
%A Jun-yan Kou
%A Dan Hong
%A Dan Su
%A Wei-min Mao
%A Xin-min Yu
%A Fa-jun Xie
%A Xiao-jian Wang
%J Journal of Zhejiang University SCIENCE B
%V 14
%N 3
%P 207-215
%@ 1673-1581
%D 2013
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1200101

TY - JOUR
T1 - Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population
A1 - Wei Hong
A1 - Kai Wang
A1 - Yi-ping Zhang
A1 - Jun-yan Kou
A1 - Dan Hong
A1 - Dan Su
A1 - Wei-min Mao
A1 - Xin-min Yu
A1 - Fa-jun Xie
A1 - Xiao-jian Wang
J0 - Journal of Zhejiang University Science B
VL - 14
IS - 3
SP - 207
EP - 215
%@ 1673-1581
Y1 - 2013
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1200101


Abstract: 
Objective: The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Methods: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods. Results: The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival. Conclusions: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Alberola, V., Sarries, C., Rosell, R., Taron, M., de las Peñas, R., Camps, C., Massuti, B., Insa, A., Garcia-Gomez, R., Isla, D., et al., 2004. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin. Lung Cancer, 5(6):360-365.

[2]Azzoli, C.G., Baker, S.J., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D.H., Laskin, J.L., Masters, G., Milton, D., et al., 2009. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol., 27(36):6251-6262.

[3]Chen, P., Wiencke, J., Aldape, K., Kesler-Diaz, A., Miike, R., Kelsey, K., Lee, M., Liu, J., Wrensch, M., 2000. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomark Prev., 9(8):843-847.

[4]Choi, S.W., Mason, J.B., 2000. Folate and carcinogenesis: an integrated scheme. J. Nutr., 130(2):129-132.

[5]Choi, S.W., Mason, J.B., 2002. Folate status: effects on pathways of colorectal carcinogenesis. J. Nutr., 132(S8):2413S-2418S.

[6]Cohen, V., Panet-Raymond, V., Sabbaghian, N., Morin, I., Batist, G., Rozen, R., 2003. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res., 9(5):1611-1615.

[7]D′Angelo, V., Ramaglia, M., Iannotta, A., Crisci, S., Indolfi, P., Francese, M., Affinita, M.C., Pecoraro, G., Napolitano, A., Fusco, C., et al., 2011. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother. Pharmacol., 68(5):1339-1346.

[8]de las Peñas, R., Sanchez-Ronco, M., Alberola, V., Taron, M., Camps, C., Garcia-Carbonero, R., Massuti, B., Queralt, C., Botia, M., Garcia-Gomez, R., et al., 2006. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small cell lung cancer patients. Ann. Oncol., 17(4):668-675.

[9]Etienne-Grimaldi, M.C., Milano, G., Maindrault-Goebel, F., Chibaudel, B., Formento, J.L., Francoual, M., Lledo, G., André, T., Mabro, M., Mineur, L., et al., 2010. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br. J. Clin. Pharmacol., 69(1):58-66.

[10]Fernández-Peralta, A.M., Daimiel, L., Nejda, N., Iglesias, D., Medina, A.V., González-Aguilera, J.J., 2010. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int. J. Colorectal. Dis., 25(2):141-151.

[11]Gandara, D.R., Kawaguchi, T., Crowley, J., Moon, J., Furuse, K., Kawahara, M., Teramukai, S., Ohe, Y., Kubota, K., Williamson, S.K., et al., 2009. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol., 27(21):3540-3546.

[12]Guilbert, J.J., 2003. The world health report 2002―reducing risks, promoting healthy life. Educ. Health (Abingdon), 16(2):230-233.

[13]Isla, D., Sarries, C., Rosell, R., Alonso, G., Domine, M., Taron, M., Lopez-Vivanco, G., Camps, C., Botia, M., Nuñez, L., et al., 2004. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol., 15(8):1194-1203.

[14]Kalikaki, A., Kanaki, M., Vassalou, H., Souglakos, J., Voutsina, A., Georgoulias, V., Mavroudis, D., 2009. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer, 10(2):118-123.

[15]Kim, H.N., Kim, Y.K., Lee, I.K., Yang, D.H., Lee, J.J., Shin, M.H., Park, K.S., Choi, J.S., Park, M.R., Jo, D.Y., et al., 2009. Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk. Res., 33(1):82-87.

[16]Kim, Y.I., 1999. Folate and carcinogenesis: evidence, mechanisms, and implications. J. Nutr. Biochem., 10(2):66-88.

[17]le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R.M., Vansteenkiste, J., Thatcher, N., et al., 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer, 47(1):69-80.

[18]Li, F., Sun, X., Sun, N., Qin, S., Cheng, H., Feng, J., Chen, B., Cheng, L., Lu, Z., Ji, J., et al., 2010. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am. J. Clin. Oncol., 33(5):489-494.

[19]Park, D.J., Zhang, W., Stoehlmacher, J., Tsao-Wei, D., Groshen, S., Gil, J., Yun, J., Sones, E., Mallik, N., Lenz, H.J., 2002. ERCC1 Polymorphism is Associated with Differential ERCC1 Gene Expression. ASCO Proceedings. American Association for Cancer Research, San Francisco, CA, p.1591.

[20]Reed, E., Dabholkar, M., Thornton, K., Thompson, C., Yu, J.J., Bostick-Bruton, F., 2000. Evidence for order in the appearance of mRNAs of nucleotide excision repair genes in human ovarian cancer tissues. Oncol. Rep., 7:1123-1128.

[21]Ryu, J.S., Hong, Y.C., Han, H.S., Lee, J.E., Kim, S., Park, Y.M., Kim, Y.C., Hwang, T.S., 2004. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 44(3):311-316.

[22]Salazar, J., Altés, A., Del Río, E., Estella, J., Rives, S., Tasso, M., Navajas, A., Molina, J., Villa, M., Vivanco, J.L., et al., 2011. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J., 12(5):379-385.

[23]Smit, E.F., Burgers, S.A., Biesma, B., Smit, H.J., Eppinga, P., Dingemans, A.M., Joerger, M., Schellens, J.H., Vincent, A., van Zandwijk, N., et al., 2009. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer. J. Clin. Oncol., 27(12):2038-2045.

[24]Smith, S., Su, D., de la Longrais, I.A.R., Schwartz, P., Puopolo, M., Rutherford, T.J., Mor, G., Yu, H., Katsaros, D., 2007. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol., 25(33):5172-5179.

[25]Spiro, S.G., Silvestri, G.A., 2005. The treatment of advanced non-small cell lung cancer. Curr. Opin. Pulm. Med., 11(4):287-291.

[26]Su, D., Ma, S., Liu, P., Jiang, Z., Lv, W., Zhang, Y., Deng, Q., Smith, S., Yu, H., 2007. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 56(2):281-288.

[27]Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., van Glabbeke, M., van Oosterom, A.T., Christian, M.C., et al., 2000. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst., 92(3):205-216.

[28]Tibaldi, C., Giovannetti, E., Vasile, E., Mey, V., Laan, A.C., Nannizzi, S., Di Marsico, R., Antonuzzo, A., Orlandini, C., Ricciardi, S., et al., 2008. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small cell lung cancer patients. Clin. Cancer Res., 14(6):1797-1803.

[29]Wang, J., Zhang, Q., Zhang, H., Wang, Q., Yang, X., Gu, Y., Zhang, S., 2010. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Chin. J. Lung Cancer, 13(4):337-341 (in Chinese).

[30]Xie, F.J., Zhao, P., Kou, J.Y., Hong, W., Fu, L., Hu, L., Hong, D., Su, D., Gao, Y., Zhang, Y.P., 2012. The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum. Cancer Chemother. Pharmacol., 69(6):1443-1448.

[31]Yin, M., Yan, J., Voutsina, A., Tibaldi, C., Christiani, D.C., Heist, R.S., Rosell, R., Booton, R., Wei, Q., 2011. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer, 72(3):370-377.

[32]Yu, J.J., Lee, K.B., Mu, C., Li, Q., Abernathy, T.V., Bostick-Bruton, F., Reed, E., 2000. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol., 16:555-560.

[33]Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D.S., Wain, J.C., Lynch, T.J., Su, L., Christiani, D.C., 2004. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res., 10(15):4939-4943.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE